Navigation Links
FDA Approved Nerve-Stimulation Therapy Now Available In New York

Vagus Nerve Stimulation therapy is a FDA approved long-term treatment regime for patients with treatment resistant depression (TRD). // This form of therapy is now being offered to patients at NewYork-Presbyterian Hospital/Columbia University Medical Center.

The treatment is now the first treatment specifically approved for TRD in patients over 18 years of age in whom antidepressant therapy has been unsuccessful atleast in four or more of the depressive episodes.

The treatment is instituted with the help of a small pacemaker-like device implanted in the chest area. The device sends mild pulses to the brain through the vagus nerve in the neck. A generator that runs under the skin to the left vagus nerve powers the device through a thin insulated wire.

The vagus nerve is one of the 12 cranial nerves and serves as the body’s information highway connecting the brain to many major organs. Several studies have shown that VNS Therapy may modulate neurotransmitters such as serotonin and norepinephrine thought to be involved in mood regulation.

Major depressive disorder is one of the most prevalent and serious illnesses in the U.S., affecting nearly 19 million Americans every year and more than 4 million people do not respond to conventional treatment such as psychotherapy, antidepressant medications, and even electroconvulsive therapy.

Nearly half of patients with an average of 25 years of major depressive disorder and multiple treatment trials realized some clinical benefit; one-third of patients had at least a 50 percent improvement in their depression; and one out of six was depression-free after treatment with VNS Therapy. Patients also reported significant improvements in quality-of-life areas, such as vitality, mental health, emotional well-being, and social functioning.

The new form of treatment is an important development in people with depression who need safe and effective therapeutic options. Several studie s have revealed the sustained beneficial efforts of the therapy over a considerable length of time. In addition, is it associated with better patient compliance and fewer side effects
'"/>




Related medicine news :

1. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
2. New FDA Approved Drug To Treat Migraine
3. New FDA Approved Drug NATRECOR For Heart Failure Patients
4. New Oral Rinse For Gingivitis Approved By FDA
5. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
6. AIDS Generic Drugs Approved by FDA for Sale in US
7. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
8. Pfizer’s Eraxis Approved By The FD
9. Inhalers for Kids Was Approved By the FDA
10. Alcoholism Drug Vivitrol Approved By FDA
11. Drug Approved to Curb Alcohol Dependency
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... Agoura Hills, CA (PRWEB) , ... January 18, ... ... risk of dental problems ranging from gum disease to enamel erosion, and those ... from the Massachusetts Department of Public Health, many pregnant women are failing to ...
(Date:1/17/2017)... ... , ... January is National Stalking Awareness Month (NSAM), now in its fourteenth year, ... commit the crime of stalking, a very real danger to many in our community. ... stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads the theme ...
(Date:1/17/2017)... ... January 17, 2017 , ... Gym Source, America’s leading retailer of premium ... South Dixie Hwy in Miami, FL. , “We are elated to be opening this ... in-store concept is designed to give clients a seamless and motivating shopping experience.” , ...
(Date:1/17/2017)... Chicago, Illinois (PRWEB) , ... January 17, 2017 , ... ... Antonio Breast Cancer Symposium (SABCS) or those who desire a more intimate review and ... Antonio: Breast Cancer – Bench to Bedside—is being offered by Imedex on February 4, ...
(Date:1/17/2017)... AZ (PRWEB) , ... January 17, 2017 , ... ... and improved supplement, Healthful-Flex. , The company, owned and operated by Ed ... public at a reasonable price with the highest level of customer service. Healthful ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 18, 2017  Tarix Orphan LLC today announced that ... Rare Pediatric Disease (RPD) designation for the company,s drug ... Bullosa (RDEB), a rare genetic skin disorder. There are ... limited to supportive care. "The RPD designation ... previously granted by the FDA in this indication," said ...
(Date:1/18/2017)... January 18, 2017 ML ... plans to publish an online presentation tomorrow, January ... sales forecast for 2017. Management reports that the ... record sales performance from its existing operations, and ... entry into the Cannabis sector through a ...
(Date:1/18/2017)...  Robust competition in the private marketplace is ... prices, according to a new study by ... the first to examine the share of prescription medicine ... managers (PBMs), health plans and other stakeholders in the ... first to show what happens when the list price ...
Breaking Medicine Technology: